neflamapimod
Small moleculeexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Dec 29, 2017 (NCT03402659)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- p38 MAP kinase alpha/betaINHIBITOR
p38 MAP kinase alpha/beta inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- neflamapimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07033481 | Phase 2 | Aug 31, 2025 | CervoMed, Inc, EIP Pharma, LLC |
| NCT06987643 | Phase 2 | Jun 20, 2025 | CervoMed, Inc, EIP Pharma, LLC |
| NCT06815965 | Phase 2 | Oct 16, 2024 | CervoMed, Inc, EIP Pharma, LLC |
| NCT05869669 | Phase 2 | May 1, 2023 | CervoMed, Inc, EIP Pharma, LLC, National Institute on Aging (NIA), Worldwide Clinical Trials |
| NCT04001517 | Phase 2 | Jun 30, 2019 | EIP Pharma, LLC, Worldwide Clinical Trials |
| NCT03980938 | Phase 2 | Jun 30, 2019 | EIP Pharma, LLC, Voisin Consulting, Inc. |
| NCT03402659 | Phase 2 | Dec 29, 2017 | EIP Pharma, LLC, Free University of Amsterdam, Worldwide Clinical Trials |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EIP Pharma, LLC | For profit | 7 | 7 | 1 | 2017 |
| CervoMed, Inc | For profit | 4 | 0 | 1 | 2023 |
| Worldwide Clinical Trials | For profit | 3 | 0 | 1 | 2017 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2017 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2023 |
| Voisin Consulting, Inc. | For profit | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1